Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: Phase 3 adapt study results

被引：0

作者：

Mantegazza, Renato ^{[1
]}

Bril, Vera ^{[2
]}

Vu, Tuan ^{[3
]}

Karam, Chafic ^{[4
]}

Peric, Stojan ^{[5
]}

Margania, Temur ^{[6
]}

Murai, Hiroyuki ^{[7
]}

Bilinska, Malgorzata ^{[8
]}

Shakarishvili, Roman ^{[9
]}

Smilowski, Marek ^{[10
]}

Guglietta, Antonio ^{[11
]}

Ulrichts, Peter ^{[11
]}

Vangeneugden, Tony ^{[11
]}

Utsugisawa, Kimiaki ^{[12
]}

Verschuuren, Jan ^{[13
]}

Howard, James ^{[14
]}

机构：

[1] Fdn IRCCS Ist Neurol Carlo Besta, Neurol Iv Neuroimmunol & Neuromuscular Dis Unit, Milan, Italy

[2] Univ Toronto, Ellen & Martin Prosserman Ctr Neuromuscular Dis, Toronto, ON, Canada

[3] Univ S Florida, Morsani Coll Med, Neurol, Tampa, FL 33620 USA

[4] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[5] Univ Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia

[6] New Hosp, Dept Neurol & Neurorehabil, Tbilisi, Georgia

[7] Int Univ Hlth & Welf, Neurol, Tokyo, Japan

[8] Wroclaw Med Univ, Dept & Clin Neurol, Wroclaw, Poland

[9] Sarajishvili Inst Neurol & Neurosurg, Neurol, Tbilisi, Poland

[10] Med Univ Silesia, Dept Hematol & Bone Marrow Transplantat, Katowice, Poland

[11] Argenx, Clin Dev, Ghent, Belgium

[12] Hanamaki Gen Hosp, Neurol, Hanamaki, Japan

[13] Leiden Univ, Med Ctr, Neurol, Leiden, Netherlands

[14] Univ N Carolina, Neurol, Chapel Hill, NC 27515 USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2021年 / 429卷

关键词：

D O I：

10.1016/j.jns.2021.117764

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

117764

引用

页数：1

共 50 条

[21] Analysis of Efgartigimod Efficacy Across Patient Populations and Myasthenia Gravis Specific Scales: Results of the Phase 3 ADAPT Study
Bril, Vera
Murai, HIroyuki
Vu, Tuan
Karam, Chafic
Peric, Stojan
Margania, Temur
Bilinska, Malgorzata
Shakarishvili, Roman
Smilowski, Marek
Guglietta, Antonio
Ulrichts, Peter
Vangeneugden, Tony
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
Howard, James F., Jr.
ANNALS OF NEUROLOGY, 2021, 90 : S28 - S28
[22] LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS: INTERIM RESULTS OF THE ADAPT-SC plus STUDY
Li, Yuebing
Howard, James F., Jr.
Vu, Tuan
Korobko, Denis
Steeland, Sophie
Van Hoorick, Benjamin
Podhorna, Jana
Hodari, Moana
Utsugisawa, Kimiaki
Sacca, Francesco
De Bleecker, Jan L.
Mantegazza, Renato
MUSCLE & NERVE, 2024, 70 (03) : 559 - 560
[23] SAFETY AND TOLERABILITY OF EFGARTIGIMOD IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS: INTEGRATED INTERIM ANALYSIS OF INFECTION RISK AND HEMATOLOGICAL CHANGES
Muppidi, Srikanth
Pasnoor, Mamatha
Gelinas, Deborah
Brauer, Edward
Kerstens, Rene
Bhavaraju-Sanka, Ratna
Howard, James
MUSCLE & NERVE, 2022, 66 : S104 - S104
[24] Prospective cohort study evaluating efficacy and safety of efgartigimod in Chinese generalized myasthenia gravis patients
Wang, Pan
Zhang, Bo
Yin, Jian
Xi, Jianying
Tan, Ying
Gao, Feng
Zeng, Fan
Chang, Ting
Zhou, Hao
Liang, Hui
Zhao, Zhongyan
Yang, Huan
Zhao, Chongbo
Huang, Shixiong
FRONTIERS IN NEUROLOGY, 2024, 15
[25] Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study
Bril, Vera
Howard Jr, James F.
Karam, Chafic
De Bleecker, Jan L.
Murai, Hiroyuki
Utsugisawa, Kimiaki
Ulrichts, Peter
Brauer, Edward
Zhao, Sihui
Mantegazza, Renato
Vu, Tuan
EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (01)
[26] LONG-TERM ASSESSMENT OF EFGARTIGIMOD IN PATIENTS WITH GENERALISED MYASTHENIA GRAVIS: ADAPT plus STUDY INTERIM RESULTS
Jacob, Saiju
Howard, James
Bril, Vera
Peric, Stojan
De Bleecker, Jan
T'joen, Carolin
Travers, Jackalyne
Utsugisawa, Kimiaki
Verschuuren, Jan
Mantegazza, Renato
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
[27] Long-term safety, and efficacy of subcutaneous Efgartigimod PH20 in patients with generalized myasthenia gravis: interim results of ADAPT-SC
Musick, K.
Howard, J.
Li, G.
Vu, T.
Korobko, D.
Smilowski, M.
Liu, L.
Steeland, S.
Noukens, J.
Van Hoorick, B.
Podhorna, J.
Li, Y.
Utsugisawa, K.
Sacca, F.
Wiendl, H.
De Bleecker, J.
Mantegazza, R.
NEUROMUSCULAR DISORDERS, 2023, 33 : S179 - S179
[28] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial (vol 20, pg 526, 2021)
Jf, Howard, Jr.
Bril, V
Vu, T.
LANCET NEUROLOGY, 2021, 20 (08): : E5 - E5
[29] Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
Howard, James F., Jr.
Bril, Vera
Burns, Ted M.
Mantegazza, Renato
Bilinska, Malgorzata
Szczudlik, Andrzej
Beydoun, Said
De Rivera Garrido, Francisco Javier Rodriguez
Piehl, Fredrik
Rottoli, Mariarosa
Van Damme, Philip
Tuan Vu
Evoli, Amelia
Freimer, Miriam
Mozaffar, Tahseen
Ward, E. Sally
Dreier, Torsten
Ulrichts, Peter
Verschueren, Katrien
Guglietta, Antonio
de Haard, Hans
Leupin, Nicolas
Verschuuren, Jan J. G. M.
Claeys, Kristl
Diez-Tejedor, Exuperio
Mathew, Veena
Sgarzi, Manlio
Harvey, Brittany Leigh
Farias, Jerrica
Frangiomore, Rita
Heintzman, Sarah
de Meel, Robert
Chopra, Manisha
Alboini, Paolo Emilio
Hietala, Albert
Genge, Angela
NEUROLOGY, 2019, 92 (23) : E2661 - E2673
[30] HOSPITALIZATION AND EXACERBATION ESTIMATES OF EFGARTIGIMOD VS. CONVENTIONAL THERAPY IN GENERALIZED MYASTHENIA GRAVIS PATIENTS: A POST-HOC ANALYSIS OF THE PHASE 3 ADAPT STUDY
Qi, C.
Dewilde, S.
Gelinas, D.
Brauer, E.
Phillips, G.
VALUE IN HEALTH, 2022, 25 (07) : S329 - S329

← 1 2 3 4 5 →